| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss from operations | -12,523 | -5,073 | -12,550 | -13,226 |
| Other income (expense), net | 365 | 389 | 2,315 | -780 |
| Loss before provision for income taxes | -12,158 | -4,684 | -10,235 | -14,006 |
| Provision for income taxes | 0 | 0 | - | - |
| Net loss | -12,158 | -4,684 | -10,235 | -14,006 |
| Basic eps | - | - | -141.57 | -0.2 |
| Diluted eps | - | - | -141.57 | -0.2 |
| Basic average shares | - | - | 1,250 | 70,975,778 |
| Diluted average shares | - | - | 1,250 | 70,975,778 |
| Net loss per share, basic (in dollars per share) | -168.01 | - | - | - |
| Net loss per share, diluted (in dollars per share) | -168.01 | - | - | - |
| Weighted-average common shares outstanding, basic (in shares) | 1,250 | - | - | - |
| Weighted-average common shares outstanding, diluted (in shares) | 1,250 | - | - | - |
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)